Precision Oncology | Dr Raman Narang – Medical Oncologist in Delhi
Precision oncology is a structured, evidence-based approach to cancer treatment that integrates tumor biology, molecular profiling, and patient-specific clinical factors.
Dr Raman Narang is a Consultant Medical Oncologist in Delhi with a focused interest in precision oncology, cancer genetics, and individualized systemic therapy. His clinical approach emphasizes rational treatment selection, biomarker-driven decisions, and careful treatment sequencing to optimize outcomes while preserving quality of life.
Precision oncology is not simply the use of newer drugs. It is the disciplined application of scientific insight to guide therapeutic strategy.
What Is Precision Oncology?
Precision oncology integrates molecular diagnostics, genomic insights, and clinical context to guide cancer treatment decisions.
Treatment planning is based on:
- Tumor type and stage
- Genomic alterations and biomarkers
- Prior treatments
- Organ function and performance status
- Patient goals and life context
The objective is to match the right therapy to the right patient at the right time.
Role of Molecular Profiling & Cancer Genetics
Modern oncology increasingly relies on tumor genetic testing and biomarker analysis to guide therapy.
Dr Raman Narang provides structured guidance on:
- Interpretation of molecular reports
- Identification of actionable mutations
- Understanding resistance mechanisms
- Determining eligibility for targeted therapies or immunotherapy
- Integrating genomic findings into overall treatment planning
This approach reduces empirical decision-making and strengthens therapeutic precision.
Immunotherapy & Targeted Therapy Selection
Immunotherapy and targeted therapies are selected based on defined biological markers rather than broad application.
Evaluation includes:
- PD-L1 and other immunotherapy biomarkers
- Tumor mutation burden where relevant
- Driver mutations (EGFR, ALK, BRAF, etc., when applicable)
- Prior lines of therapy
- Potential benefit versus toxicity profile
Careful patient selection improves outcomes and minimizes unnecessary treatment exposure.
Structured Treatment Planning Approach
Precision oncology requires sequencing — not simply drug selection.
Clinical planning includes:
- First-line therapy strategy
- Anticipation of resistance patterns
- Planning subsequent lines of treatment
- Toxicity management
- Integration with surgery or radiation when appropriate
Each case is evaluated individually rather than through protocol-driven uniformity.
Who Benefits from Precision Oncology?
Precision oncology is particularly valuable in:
- Advanced or metastatic cancers
- Rare tumor subtypes
- Treatment-resistant disease
- Patients seeking second opinion clarification
- Younger patients requiring long-term survivorship planning
Second Opinion in Complex Cases
Many patients seek a structured second opinion to review:
- Molecular test interpretation
- Suitability of immunotherapy
- Alternative treatment sequencing
- Clinical trial eligibility
- Risk-benefit balance of proposed therapy
Dr Raman Narang provides detailed, evidence-based second opinion consultations for patients in India and internationally.
Consultation Pathways
Patients may schedule:
- In-person consultation in Delhi
- Structured second opinion review
- International case review
Cancer Treatment Across Age Groups
Geriatric Oncology (Older Adults)
Cancer treatment in older adults should be guided by functional assessment rather than chronological age.
Dr Raman Narang integrates:
- Performance status and frailty assessment
- Comorbidity burden
- Organ function evaluation
- Risk of treatment-related toxicity
- Goals of care and quality-of-life priorities
Therapeutic decisions are individualized to balance disease control with safety, independence, and dignity.
Age alone should not determine intensity of therapy — structured assessment should.
Adolescent & Young Adult (AYA) Oncology
Young adults face unique medical and life-stage considerations during cancer treatment.
Planning includes attention to:
- Fertility preservation
- Long-term toxicity risks
- Career and educational disruption
- Survivorship planning
- Psychosocial impact
Precision oncology plays a particularly important role in younger patients where long-term outcomes and treatment sequencing are critical.
As a Consultant Medical Oncologist in Delhi, Dr Raman Narang incorporates age-specific evaluation into precision treatment planning.
Frequently Asked Questions – Precision Oncology
1. What is precision oncology and how is it different from standard cancer treatment?
Precision oncology is a treatment approach that uses the genetic and molecular characteristics of a tumor to guide therapy selection. Unlike traditional cancer treatment, which is often based primarily on tumor type and stage, precision oncology evaluates biomarkers, gene mutations, and molecular pathways driving cancer growth.
This allows treatment to be individualized using targeted therapy, immunotherapy, or biomarker-driven strategies rather than relying solely on conventional chemotherapy protocols.
2. Does every cancer patient require molecular testing?
Not every cancer requires extensive molecular testing, but many common cancers now routinely depend on biomarker evaluation. These include lung cancer, breast cancer, colorectal cancer, melanoma, ovarian cancer, and several others.
Testing decisions are based on tumor type, stage, histology, and current evidence-based guidelines. Appropriate molecular profiling ensures that actionable mutations or predictive biomarkers are not missed when selecting therapy.
3. Can precision oncology improve treatment outcomes?
In selected cancers, yes. Identifying actionable mutations can significantly improve response rates and progression-free survival. For example, targeted therapies in EGFR-mutated lung cancer or HER2-positive breast cancer have transformed outcomes compared to historical chemotherapy-alone approaches.
However, precision oncology does not replace standard therapy in all cases. It complements or refines treatment selection based on tumor biology.
4. What is the difference between genetic testing and molecular profiling?
Molecular profiling evaluates genetic changes within the tumor itself to guide treatment decisions. Genetic testing (germline testing) evaluates inherited mutations that may increase cancer risk.
Both are important but serve different purposes. Tumor testing helps select therapy, while germline testing helps identify hereditary cancer syndromes and guide family risk assessment.
5. Is precision oncology only useful in advanced-stage cancer?
No. While molecular testing is often critical in advanced-stage disease, it is increasingly relevant in early-stage cancers as well. Biomarkers can influence adjuvant therapy decisions, recurrence risk assessment, and eligibility for targeted treatment even after surgery.
Precision oncology is not defined by stage — it is defined by biology.
Related Reads
When Immunotherapy Works Even With Low PD-L1 Expression
The Role of PD-L1 Testing Before Starting Immunotherapy
Molecular Subtypes of Breast Cancer and Their Treatment Implications